Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNP | P00491 | 6/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.61 |
| ▸ | HPGD | P15428 | 1/20 | 0.58 |
| ▸ | TYMS | P04818 | 1/20 | 0.52 |
| ▸ | PARN | O95453 | 1/20 | 0.48 |
| ▸ | CNOT7 | Q9UIV1 | 1/20 | 0.48 |
| ▸ | BRD4 | O60885 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL5718893 | 0.99 | PNP (0.63) | PNPSMN1; SMN2ALDH1A1KMT2AHPGD | |
| Hydrochloric Acid SCHEMBL7773119 | 0.99 | PNP (0.63) | PNPSMN1; SMN2ALDH1A1KMT2AHPGD | |
| SCHEMBL7111111 | 0.92 | PNP (0.56) | PNPSMN1; SMN2ALDH1A1KMT2AHPGD | |
| Hydrochloric Acid SCHEMBL7114730 | 0.91 | PNP (0.55) | PNPSMN1; SMN2ALDH1A1KMT2AHPGD | |
| SCHEMBL16028279 | 0.88 | TYMS (0.53) | PNPSMN1; SMN2ALDH1A1KMT2AHPGD | |
| SCHEMBL27746499 | 0.87 | PNP (0.55) | PNPSMN1; SMN2ALDH1A1KMT2AHPGD | |
| SCHEMBL7111737 | 0.86 | PNP (0.49) | PNPSMN1; SMN2ALDH1A1KMT2AHPGD | |
| Hydrochloric Acid SCHEMBL6258586 | 0.85 | PNP (0.48) | PNPSMN1; SMN2ALDH1A1KMT2AHPGD | |
| SCHEMBL7988094 | 0.84 | SMN1; SMN2 (0.60) | PNPSMN1; SMN2ALDH1A1KMT2AHPGD | |
| SCHEMBL7974022 | 0.84 | SMN1; SMN2 (0.62) | PNPSMN1; SMN2ALDH1A1KMT2AHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 90 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250034143-A1 | SUBSTITUTED XANTHINES AND METHODS OF USE THEREOF | HYDRA BIOSCIENCES, LLC (US) | 2025-01-30 | — | — | US | disclosed |
| US-11958854-B2 | Substituted xanthines and methods of use thereof | HYDRA BIOSCIENCES, LLC (US) | 2024-04-16 | — | — | US | disclosed |
| EP-3894410-B1 | SUBSTITUTED XANTHINE DERIVATIVES | BOEHRINGER INGELHEIM INT (DE) | 2023-10-11 | — | — | EP | disclosed |
| EP-4233871-A2 | INHIBITING THE TRANSIENT RECEPTOR POTENTIAL A1 ION CHANNEL | Eli Lilly and Company (US) | 2023-08-30 | — | — | EP | disclosed |
| US-20230040259-A1 | SUBSTITUTED XANTHINES AND METHODS OF USE THEREOF | HYDRA BIOSCIENCES, LLC (US) | 2023-02-09 | — | — | US | disclosed |
| US-20230040259-A1 | SUBSTITUTED XANTHINES AND METHODS OF USE THEREOF | HYDRA BIOSCIENCES, LLC (US) | 2023-02-09 | — | — | US | disclosed |
| US-20220177479-A1 | NOVEL SUBSTITUTED XANTHINE DERIVATIVES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2022-06-09 | — | — | US | disclosed |
| US-11208409-B2 | Substituted xanthines and methods of use thereof | HYDRA BIOSCIENCES, LLC (US) | 2021-12-28 | — | — | US | disclosed |
| US-11208409-B2 | Substituted xanthines and methods of use thereof | HYDRA BIOSCIENCES, LLC (US) | 2021-12-28 | — | — | US | disclosed |
| EP-3652176-B1 | SUBSTITUTED XANTHINE DERIVATIVES | BOEHRINGER INGELHEIM INT (DE) | 2021-12-15 | — | — | EP | disclosed |
| US-5831092-A | Process for producing purine derivatives | AJINOMOTO CO., INC. (JP) | 1998-11-03 | — | — | US | disclosed |
| EP-0827960-A1 | Process for producing purine derivatives | Ajinomoto Co., Inc. (JP) | 1998-03-11 | — | — | EP | disclosed |
| EP-0523100-B1 | O6 -BENZYLATED GUANINE, GUANOSINE AND 2'-DEOXYGUANOSINE COMPOUNDS POSSESSING O6 -ALKYLGUANINE-DNA ALKYLTRANSFERASE DEPLETING ACTIVITY | US HEALTH (US) | 1996-08-28 | — | — | EP | disclosed |
| EP-0728757-A1 | Process for producing purine derivatives | Ajinomoto Co., Inc. (JP) | 1996-08-28 | — | — | EP | disclosed |
| US-5358952-A | Anticarcinogenic agents | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1994-10-25 | — | — | US | disclosed |
| US-5352669-A | Increases host responsiveness to anti-neoplastic alkylating agents including chloroethylating agents for chemotheraputical treatment | THE OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1994-10-04 | — | — | US | disclosed |
| EP-0523100-A4 | O?6 -BENZYLATED GUANINE, GUANOSINE AND 2'-DEOXYGUANOSINE COMPOUNDS POSSESSING O?6 -ALKYLGUANINE-DNA ALKYLTRANSFERASE DEPLETING ACTIVITY | US HEALTH (US) | 1993-03-17 | — | — | EP | disclosed |
| EP-0523100-A1 | O?6 -BENZYLATED GUANINE, GUANOSINE AND 2'-DEOXYGUANOSINE COMPOUNDS POSSESSING O?6 -ALKYLGUANINE-DNA ALKYLTRANSFERASE DEPLETING ACTIVITY. | US HEALTH (US) | 1993-01-20 | — | — | EP | disclosed |
| US-5091430-A | Increase response to antitumor agents | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1992-02-25 | — | — | US | disclosed |
| WO-1991013898-A1 | O6-BENZYLATED GUANINE, GUANOSINE AND 2'-DEOXYGUANOSINE COMPOUNDS POSSESSING O6-ALKYLGUANINE-DNA ALKYLTRANSFERASE DEPLETING ACTIVITY | THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, UNITED STATES DEPARTMENT OF COMMERCE (US) | 1991-09-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11958854-B2 | Substituted xanthines and methods of use thereof | TRPC5, TRPC7, TRPC4 | PNP 762/4885SMN1; SMN2 1307/4885ALDH1A1 1647/4885 |
| US-20230040259-A1 | SUBSTITUTED XANTHINES AND METHODS OF USE THEREOF | TRPC5, TRPC7, TRPC4 | PNP 762/4885SMN1; SMN2 1307/4885ALDH1A1 1647/4885 |
| US-20250034143-A1 | SUBSTITUTED XANTHINES AND METHODS OF USE THEREOF | TRPC5, TRPC7, TRPC4 | PNP 762/4885SMN1; SMN2 1307/4885ALDH1A1 1647/4885 |
| US-11208409-B2 | Substituted xanthines and methods of use thereof | TRPC5, TRPC7, TRPC4 | PNP 762/4885SMN1; SMN2 1307/4885ALDH1A1 1647/4885 |
| US-20220177479-A1 | NOVEL SUBSTITUTED XANTHINE DERIVATIVES | TRPC5, TRPC4, TRPM5 | PNP 1305/4885SMN1; SMN2 1473/4885ALDH1A1 962/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.